Jennifer I Lim
Has grant
Vice Chair; Marion H Schenk Chair in Ophthalmolgy, Director of Retina Service
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Differential artery-vein analysis in OCT angiography for objective classification of diabetic retinopathy
Open Date: 2020-02-01
Close Date: 2024-01-31
Articles (19)
Year:
2026
Year:
2026
Year:
2026
Purpose: To investigate the potential utility of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR). Methods: Retrospective review of anatomical and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes. Results: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean = 21 months). Within 1 month after anti-VEGF treatment, VA improved ≥2 lines in 18/45 eyes, remained stable in 26/45 eyes, and worsened in 1/45 eyes. The median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement posttreatment than stage 3 PSR eyes ( P = 0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy. Conclusion: Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.
Year:
2026
Year:
2025
Year:
2025
Purpose: Outcomes of sutureless scleral-fixated intraocular lens have primarily focused upon short-term results. This retrospective, observational clinical study focuses upon the long-term visual acuity and anatomic outcomes of sutureless scleral-fixated intraocular lenses. Methods: A comprehensive medical record review of patients that underwent sutureless scleral-fixated intraocular lens placement by a single surgeon from 2015 through 2024 was performed. Pre- and postoperative best-corrected visual acuity, anatomic outcomes, and complications were documented. Statistical analysis was performed. Results: Forty-three patients (ages 18–91 years, mean = 63) with follow-up ranging from 1 to 100.5 months (mean = 27.5, median = 14.67) met inclusion criteria. Mean preoperative best-corrected visual acuity was 1.11 logarithm of the minimum angle of resolution units (Snellen ratio: 20/250) ± 0.59 SD. Mean postoperative best-corrected visual acuity improvement was statistically significant at 1, 3, 6, 9 months, and 1, 2, 3 years. Postoperative complications included hyphema (n = 3), vitreous hemorrhage (n = 14), transient ocular hypertension (n = 8) and hypotony (n = 5), haptic erosion (n = 3), intraocular lens dislocation or damage (n = 4), and cystoid macular edema (n = 8). All complications were identified within 1.25 years of follow-up excluding 2 cases of cystoid macular edema. Conclusion: Sutureless scleral-fixated intraocular lens patients demonstrated statistically significant and gradual best-corrected visual acuity improvement up to 3 years postoperatively. Cases of cystoid macular edema were identified up to 3 years postoperatively.
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (14)
Fumi Gomi
Hyogo medical university
XINCHENG YAO
Richard & Loan Hill Professor
University of Chicago
Tiarnan Keenan
National Institutes of Health
Cecilia Lee
Professor
University of Washington
Samantha Fraser‐Bell
University of Sydney
Mojtaba Rahimi
University of Chicago
Andreas Pollreisz
Associate Professor
Medical University of Vienna
Aaron Lee
Assistant Professor
University of Washington
Amitha Domalpally
Associate Professor
University of Wisconsin-Madison
Emily Chew
NIH Distinguished Investigator
-
Michael Abramoff
Staff Ophthalmologist
University of Iowa Healthcare
Avni Finn
Associate Professor
Vanderbilt University School of Medicine
Joel Schuman
Professor of Biomedical Engineering
Drexel University
Anat Loewestein
-
Make your next move.
Prepare your application
Review drafts before you send them.